CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy-Reference-Cited by-同舟云学术

CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy

Published:2020-01 Issue:1 Volume:21 Page:7-21
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Genvigir Fabiana Dalla Vecchia¹,Campos-Salazar Antony Brayan¹²,Felipe Claudia Rosso³,Tedesco-Silva Helio³,Medina-Pestana José Osmar³,Doi Sonia de Quateli⁴,Cerda Alvaro⁵,Hirata Mario Hiroyuki¹,Herrero María José⁶,Aliño Salvador Francisco⁶,Hirata Rosario Dominguez Crespo¹

Affiliation:

1. Department of Clinical & Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil

2. Bioinformatics & Pharmacogenetics Laboratory, METOSMOD Research Group, School of Pharmacy & Biochemistry, Universidad Nacional Mayor de San Marcos, Lima, Peru

3. Nephrology Division, Hospital do Rim, Federal University of Sao Paulo, Sao Paulo, Brazil

4. Nephrology Research Laboratory, School of Medicine, Uniformed Services University, Bethesda, MD, USA

5. Department of Basic Sciences, Center of Excellence in Translational Medicine, BIOREN, Universidad de La Frontera, Temuco, Chile

6. Department of Pharmacology, University of Valencia. Pharmacogenetics, Instituto Investigación Sanitaria y Hospital La Fe, Valencia, Spain

Abstract

Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & methods: Brazilian kidney recipients were treated with TAC combined with everolimus (n = 178) or mycophenolate sodium (n = 97). The variants in CYP2C8, CYP2J2, CYP3A4, CYP3A5, POR, ABCB1, ABCC2, ABCG2, SLCO1B1 and SLCO2B1 were analyzed. Main results: CYP3A5*3/*3 genotype influenced increase in TAC concentration from week 1 to month 6 post-transplantation (p < 0.05). The living donor and CYP2C8*3 variant were associated with reduced risk for delayed graft function (OR = 0.07; 95% CI = 0.03–0.18 and OR = 0.45; 95% CI = 0.20–0.99, respectively, p < 0.05). Conclusion: The CYP3A5*3 variant is associated with increased early exposure to TAC. Living donor and CYP2C8*3 variant seem to be protective factors for delayed graft function in kidney recipients.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2019-0120

Reference53 articles.

1. Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation

2. Prevention of complications from use of conventional immunosuppressants: a critical review

3. Tailoring tacrolimus therapy in kidney transplantation

4. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines forCYP3A5Genotype and Tacrolimus Dosing

5. Kidney Transplant Recipients Carrying theCYP3A4*22Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine;Pharmacological Research;2024-02

2. Kidney transplantation: the recipient;Living Donor Organ Transplantation;2024

3. Pharmacokinetics and Safety of Tucatinib in Healthy Japanese and Caucasian Volunteers: Results From a Phase Ⅰ Study;Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics;2023-09-30

4. Loss of Function ABCG2 c.421C>A (rs2231142) Polymorphism Increases Steady-State Exposure to Mycophenolic Acid in Stable Renal Transplant Recipients: An Exploratory Matched Cohort Study;Advances in Therapy;2022-11-25

5. Loss of function ABCG2 c.421C>A (rs2231142) polymorphism increases steady-state exposure to mycophenolic acid in stable renal transplant recipients: exploratory matched cohort study;2022-11-16